Wall Street Zen upgraded shares of Sunshine Biopharma (NASDAQ:SBFM – Free Report) to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.
Separately, Weiss Ratings raised shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.
Get Our Latest Analysis on SBFM
Sunshine Biopharma Stock Down 12.0%
NASDAQ SBFM opened at $2.93 on Friday. The company’s 50 day moving average is $14.16 and its 200-day moving average is $109.35. Sunshine Biopharma has a 12-month low of $2.58 and a 12-month high of $464.00. The firm has a market cap of $644,600.00, a P/E ratio of -0.01 and a beta of 1.20.
Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($23.00) EPS for the quarter, beating analysts’ consensus estimates of ($24.00) by $1.00. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. The company had revenue of $9.26 million for the quarter, compared to analysts’ expectations of $8.70 million. Equities analysts expect that Sunshine Biopharma will post -39.00 EPS for the current year.
About Sunshine Biopharma
Sunshine Biopharma, Inc is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.
In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.
Further Reading
- Five stocks we like better than Sunshine Biopharma
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
